BioInvest In The News

The Life Sciences Report (6-19-14)
Moneyshow - Three Favorites from a Biotech Expert (3-12-14)
Dick Davis Investment Digest (1-22-14)
The Life Sciences Report (1-15-14)
Moneyshow - Top Pros' Top Picks (1-6-14)
Moneyshow - Top Pros' Top Picks (1-10-14)
Company Updates
Novavax Update (6-5-14)

Novavax Update (6-5-14)

Novavax (NVAX) – Follow-On Offering Creates Buying Opportunity; Proceeds Will Accelerate “Respiratory Vaccine” Timeline Last night, Novavax announced a $100 million secondary offering of common stock. The underwriters are JPMorgan and Citibank, two global investment banks that currently do not cover the stock from a research standpoint. After speaking with management, the use of proceeds is [...]

Pharmacyclics Update (5-23-14)

Pharmacyclics Update (5-23-14)

PCYC – EHA Abstracts & Marketing VP Quits – Can It Get Any Noisier Right Before ASCO? The availability of EHA abstracts and the announcement that Paula Boultbee, a VP of Marketing, has resigned – taken together has led to significant pressure on PCYC stock. After the ASCO abstracts revealed to us that Imbruvica’s competitive [...]

Pharmacyclics Update (5-2-14)

Pharmacyclics Update (5-2-14)

PCYC – Imbruvica Handily Beats Consensus, Co. Issues Ultra-Conservative Guidance, Autoimmune Underway, ASCO Nearing & An MM Signal Note – The Shorts Last Gasp PCYC shares have come under pressure after posting $56 m. in Imbruvica sales ($52 m. end user sales), well above $41 m. consensus. The company issued initial guidance for the rest [...]